Using NSCLC cell lines carrying GOF EGFR mutants and transgenic mice expressing EGFRL858R, we provide evidence that EGFR mutants activate Shp2 in human lung adenocarcinoma cells and in mouse lung tissues. This evidence concerns the gene EGFR and non-small cell lung carcinoma.